Wednesday, May 31, 2006

4:00 – 6:00 pm  MSG Executive Committee meeting – L3 (lower level of main lodge)

6:30 – 7:30  Social hour – main lodge

7:30 pm  Dinner – main lodge

Thursday, June 1, 2006

7:00 am  New MSG member/MSG Visitor Information Breakfast – Drake Room
         R. Griggs, M. McDermott, R. Tawil, C. Jackson, R. Barohn,
         J. Kissel, M. Rose, L. Herbelin, Don Sanders, Anthony Amato, Wendy King
         and Pam Kitrell

7:30 – 8 am  Breakfast - main lodge

8 am – 8:15 am  Welcome and Introductions – R. Griggs - Auditorium – across from main lodge

8:15 – 8:45 am  State of MSG (Plenary) – R. Tawil

8:45 – 9:30 am  Committees Reports (Plenary)
          Nominating Committee – S Greenberg
          Publications Committee – D. Sanders
          Constitution Committee – C. Jackson/D. Sanders

9:30 am – 12:15 pm  Contemporary Issues in Clinical Trial Design - Moderator – M. McDermott

  9:30-10 am  Wilson Bryan – Drug development for myopathies: A regulatory perspective

  10 – 10:30 am  Bruce Levin – Innovative statistical designs for studies of
                  small numbers of patients

  10:30-11 am  Shree Pandya  – Outcome measures and trial designs – finding the right mix

  11 – 11:30 am  Richard Moxley/John Porter – Issues in translational research

  11:30 – 12 noon  James Cleland – The n of 1 trial

  12 – 12:15  Panel Discussion

12:15 – 1:30 pm  Lunch - main lodge
1:30 – 5:00 pm  MSG project Steering Committee/investigators’ meetings:
1:30 – 2 pm  FOR-DMD – R. Griggs/M. McDermott
2 – 2:30 pm  CMT trial - M. Shy/R. Lewis
2:30 – 3 pm  MG-mycophenolate – D. Sanders
3 – 3:30 pm  Arimoclomol Therapy for IBM - R. Barohn
3:30 – 4 pm  Dermatomyositis – Etanercept investigators’ meeting – A. Amato
4 – 4:30 pm  SMA – P. Kaufmann
4:30 – 5 pm  InQol – M. Rose

5- 6 pm  Free Time
6 pm  Social hour
7:00 pm  Dinner

Friday, June 2, 2006

7:00 – 8 am  Breakfast – main lodge
8:00 – 8:30 am  Review of MSG Conflict of Interest Policy - Auditorium - across from main lodge
8:30 – 11:45 am  Translational Research in Neuromuscular Disease – Moderator, Charles Thornton
       8:30 – 9:00 am  Edward Kaye - Regulatory approval for a neuromuscular treatment:
                       Lessons learned from Pompe Disease
       9 – 9:30 am  Karl Kieburtz - Perspectives on FDA reviews and approval process

       9:30 – 10 am  Jerry Mendell – Therapeutic developments in Duchenne and Limb Girdle muscular dystrophy

10 – 10:30 am  Lee Sweeney - Phase 1 clinical trials
10:30 -11 am  Duygu Selcen - Myofibrillar myopathies
11: – 11:30 pm  Andrew Engel – Congenital myasthenias
11:30-11:45 pm  Panel Discussion

11:45 – 1 pm  Lunch/Group Photo
1 – 1:15 pm  NIH/NINDS Report – John Porter
1:15 – 1:30 pm  NIH/NINDS Report on NIH-funded ALS trials – Robin Conwit
1:30 – 1:45 pm  NIH/NIAMS Report – Glen Nuckolls
1:45 – 2 pm  MDA Report – Valerie Cwik
2 – 3:00 pm  Investigator meetings (Continued):
       HYP HOP Trial – R. Griggs
       CINCH – R. Griggs/B. Herr